Cargando…
Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
BACKGROUND: Trastuzumab-induced cardiotoxicity (TIC) can lead to early discontinuation of adjuvant therapy, however there is limited evidence on long-term survival outcomes in patients with operable human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) experiencing treatment in...
Autores principales: | Sardesai, Sagar, Sukumar, Jasmine, Kassem, Mahmoud, Palettas, Marilly, Stephens, Julie, Morgan, Evan, Addison, Daniel, Baliga, Ragavendra, Stover, Daniel G., VanDeusen, Jeffrey, Williams, Nicole, Cherian, Mathew, Lustberg, Maryam, Wesolowski, Robert, Ramaswamy, Bhuvaneswari |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643282/ https://www.ncbi.nlm.nih.gov/pubmed/33292843 http://dx.doi.org/10.1186/s40959-020-00081-9 |
Ejemplares similares
-
LPTO-10. ASSESSMENT OF LEPTOMENINGEAL CARCINOMATOSIS DIAGNOSIS AND OUTCOMES FROM 2005 TO 2015 AT THE OHIO STATE UNIVERSITY
por: Williams, Nicole, et al.
Publicado: (2019) -
Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study
por: Morgan, Evan, et al.
Publicado: (2020) -
Estrogen Receptor Beta (ERβ): A Ligand Activated Tumor Suppressor
por: Mal, Rahul, et al.
Publicado: (2020) -
A Cardiac Rehabilitation Program for Breast Cancer Survivors: A Feasibility Study
por: Zvinovski, Filadelfiya, et al.
Publicado: (2021) -
Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer
por: Wesolowski, Robert, et al.
Publicado: (2020)